Royalty, contract and other revenues — Total revenues
Gilead Sciences Royalty, contract and other revenues — Total revenues decreased by 36.4% to $14.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 74.1%, from $54.00M to $14.00M. Over 3 years (FY 2022 to FY 2025), Royalty, contract and other revenues — Total revenues shows an upward trend with a 20.8% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates successful monetization of intellectual property or expanded collaborative partnerships, while a decrease may suggest expiring patents or reduced reliance on third-party licensing models.
Detailed definition
This metric represents the total revenue generated from licensing intellectual property, contractual arrangements, and a...
Peer comparison
Peers in the biopharmaceutical industry often report this as 'Other Revenue' or 'Licensing and Royalty Income,' which typically fluctuates based on the lifecycle of licensed drugs and the timing of milestone payments.
gild_segment_royalty_contract_and_other_revenues_total_revenuesHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $74.75M | $74.75M | $74.75M | $74.75M | $45.50M | $45.50M | $45.50M | $45.50M | $39.00M | $41.00M | $30.00M | $34.00M | $54.00M | $27.00M | $424.00M | $22.00M | $14.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -39.1% | +0.0% | +0.0% | +0.0% | -14.3% | +5.1% | -26.8% | +13.3% | +58.8% | -50.0% | >999% | -94.8% | -36.4% |
| YoY Change | — | — | — | — | -39.1% | -39.1% | -39.1% | -39.1% | -14.3% | -9.9% | -34.1% | -25.3% | +38.5% | -34.1% | >999% | -35.3% | -74.1% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's royalty, contract and other revenues — total revenues?
- Gilead Sciences (GILD) reported royalty, contract and other revenues — total revenues of $14.00M in Q1 2026.
- How has Gilead Sciences's royalty, contract and other revenues — total revenues changed year-over-year?
- Gilead Sciences's royalty, contract and other revenues — total revenues decreased by 74.1% year-over-year, from $54.00M to $14.00M.
- What is the long-term trend for Gilead Sciences's royalty, contract and other revenues — total revenues?
- Over 3 years (2022 to 2025), Gilead Sciences's royalty, contract and other revenues — total revenues has grown at a 20.8% compound annual growth rate (CAGR), from $299.00M to $527.00M.
- What does royalty, contract and other revenues — total revenues mean?
- Revenue earned from licensing intellectual property, royalties, and contractual service agreements rather than direct product sales.